Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.

The key to treating congestive heart failure is addressing the underlying causes, and treatment is highly tailored to each patient's needs. Chris Bell, an acute care nurse practitioner who specializes ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Background Early heart failure (HF) diagnosis is crucial to ensure that optimal guideline-directed medical therapy (GDMT) is ...

The following is a summary of “Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

A new biological patch, designed from heart cells grown in the laboratory, could bring a glimmer of hope in the treatment of ...

Middle aged and older adults who are hospitalized for severe infections were more than twice as likely to develop heart failure in the future, a new study shows. Authors say that’s why it’s so ...

Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

How would you further evaluate and treat this patient? Heart failure with preserved ejection fraction is a heterogeneous syndrome. The diagnosis of the condition requires ruling out potential ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

February is American Heart Month and a good time to raise awareness about heart disease, the nation’s leading cause of death.